Trial Profile
Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Clofarabine (Primary)
- Indications Langerhans cell histiocytosis
- Focus Therapeutic Use
- 28 Jul 2020 Status changed from recruiting to active, no longer recruiting.
- 17 Jun 2019 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 17 Jun 2019 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2021.